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Abstract
Purpose: SIX2 and CITED1 are transcriptional regulators that specify self-renewing nephronic
progenitor cells of the embryonic kidney. We hypothesized that SIX2, which promotes and maintains
this stem cell population, and CITED1 remain active in Wilms' tumor (WT).
Methods: To evaluate expression domains and the pathogenic significance of SIX2 and CITED1 across
WT, the Children's Oncology Group provided 40 WT specimens of stages I to IV (n = 10 per stage),
which were enriched for unfavorable histology (n = 20) and treatment failure (relapse or death, n = 20).
SIX2 and CITED1 protein expression was evaluated qualitatively (immunohistochemistry) and
quantitatively (Western blot, or WB). Gene transcription was estimated using quantitative real-time
polymerase chain reaction (qRT-PCR).
Results: SIX2 was visualized by immunohistochemistry in 36 (94.7%) of 38 specimens. Protein and
messenger RNA expression of SIX2 were quantitatively similar across all stages of disease (P = .48 WB;
P = 0.38 qPCR), in favorable or unfavorable histology (P = 0.51 WB; P = 0.58 qPCR), and in treatment
failure or success (P = 0.86 WB; P = 0.49 qPCR). Although CITED1 expression paralleled SIX2
qualitatively, no quantitative correlation between SIX2 and CITED1 expression was observed (Spearman
correlation coefficient, 0.28; P = 0.08). As in the fetal kidney, overlapping, but also distinct, WT cellular
expression domains were observed between SIX2 and CITED1.
Conclusion: SIX2 and CITED1 remain active across all disease characteristics of WT. Activity of these
genes in WT potentially identifies a population of self-renewing cancer cells that exhibit an embryonic,
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stemlike phenotype. Taken together, these transcriptional regulators may be fundamental to WT cellular
self-renewal and may represent targets for novel therapies that promote terminal differentiation.
© 2012 Elsevier Inc. All rights reserved.
Wilms' tumor (WT) is the most common kidney cancer
of childhood and is thought to arise from arrested epithelial
differentiation of nephronic progenitor cells of the
embryonic kidney [1,2]. Normal nephron development
results from reciprocal inductive signaling between the
ureteric bud tip epithelium and the surrounding condensing
metanephric mesenchyme (MM) [3]. The condensing or
cap mesenchyme must balance the dual fates of either
epithelial differentiation into functional nephrons or self-
renewal, which maintains the pool of nephronic pro-
genitors until kidney maturation is complete [4]. During
kidney development, expression of 2 transcriptional
regulators, SIX2 and CITED1, specifies the self-renewing
population of nephronic progenitor cells within the
condensing MM [4]. SIX2 has been shown to be a direct
regulator of nephronic progenitor self-renewal and has
been shown to suppress epithelial differentiation and
promote maintenance of the MM [5]. Fate mapping of
CITED1- and SIX2-positive cells within the MM was used
to discover the self-renewing capacity of the MM [5,6]. In
separate studies, however, CITED1 null mice did not
exhibit altered nephrogenesis, signifying that CITED1
expression is not solely responsible for maintenance of
nephronic progenitors [7]. In contrast, SIX2 null mice
exhibit marked metanephric hypoplasia, indicating that
SIX2 is required for progenitor cell self-renewal [5,8].
Wilms' tumor caricatures the classic triphasic histology
of the embryonic kidney (blastema, epithelia, stroma), with
the blastemal compartment representing the neoplastic
analogue of the MM in development [9]. Clarifying
signaling pathways, which function as gatekeepers of
progenitor self-renewal and mesenchymal to epithelial
transition, may yield clues as how to promote terminal
differentiation of WT, lessons potentially applicable to
other embryonal tumors. Importantly, although SIX2 and
CITED1 become inactive in the earliest phases of epithelial
and nephronic maturation and are “off” in the mature
kidney, we have previously shown that CITED1 remains
active in WT and richly labels WT blastema [10]. In those
studies, increased CITED1 expression was associated with
stage IV disease in favorable histology WT [10].
Mechanistically, we have shown that overexpression of
wild-type CITED1 is proproliferative in the malignant
context and that deletion of the CITED1 transactivation
domain attenuates Wilms' tumorigenesis [11]. However,
the functional and pathogenic significance of SIX2 in WT
development and disease progression has yet to be defined.
In this study, we aimed to characterize SIX2 expression in
the context of CITED1 and also to determine if expression
patterns of either gene had pathogenic features in favorable
and unfavorable histology WT.
1. Methods
1.1. Acquisition of tissue specimens
The institutional review board of Vanderbilt University
Medical Center approved all studies involving human tumor
and embryonic kidney specimens (institutional review board
no. 020888). To explore SIX2 and CITED1 activity in WT
and their association with adverse clinical features, the
Children's Oncology Group provided 40 corresponding
paraffin-embedded and fresh-frozen WT specimens from
stages I to IV of disease (n = 10 per stage), which were
enriched for unfavorable histology (n = 20), and treatment
failure (disease relapse or death, n = 20). Specimens were
deidentified, and the investigative team was blinded to all
clinical details of patient samples until after data analysis had
been completed.
Discarded human fetal kidneys (having gestational ages
16, 20, and 24 weeks) were procured from therapeutic
abortuses (Advanced Bioscience Resources, Inc, Alameda,
CA). Specimens were shipped overnight in sterile media on
ice and fixed immediately on arrival in 10% buffered
formalin. Mouse fetal kidneys (MFKs) from gestational ages
e13 to e18.5 (days postconception) were similarly processed
and used for experimental analysis.
1.2. Immunohistochemistry
We immunostained the aforementioned WT and fetal
kidney specimens to characterize the cellular expression
domains of SIX2 and CITED1 in the malignant and
embryonic contexts. All tissue samples were subjected to
heat-induced epitope retrieval in 10 mM citrate buffer. As
described previously [10], these 5-μm sections were
incubated in affinity-purified rabbit anti-CITED1 (1:50
dilution; Lab Vision Corp, Fremont, CA) or rabbit anti-
SIX2 (1:25 dilution; US Biological Corp, Marblehead,
MA) antibodies for 1 hour at room temperature. Goat
antirabbit secondary antibody (1:200 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA) was applied to tissues at
room temperature for 45 minutes. Tissues were visualized
with either a Vectastain ABC kit (Vector Laboratories,
Burlingame, CA) or DAKO Envision kit (DAKOCytoma-
tion, Carpinteria, CA). Because SIX2 has not been
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previously characterized in WT by immunohistochemistry,
we validated our observations using a second anti-SIX2
antibody (1:150 dilution, mouse monoclonal; Abnova,
Walnut, CA).
1.3. Immunofluorescence
To colocalize the distribution of SIX2 and CITED1
expression among cell populations of human WT and fetal
kidney specimens, we performed double immunofluores-
cence. Five-micrometer paraffin-embedded sections were
deparaffinized and rehydrated. Sections were subjected to
heat-induced epitope retrieval as described above. Endoge-
nous tissue peroxidase activity was quenched using 3%
hydrogen peroxide in methanol. Human fetal kidney andWT
sections were blocked using 10% goat serum in phosphate-
buffered saline (PBS) for 1 hour at room temperature. These
sections were then incubated in affinity-purified rabbit anti-
CITED1 (1:2500 dilution; Lab Vision Corp) and mouse anti-
SIX2 (1:5000 dilution; Abnova) in 10% goat serum and PBS
overnight at 4°C. DAKO Envision antimouse horseradish
peroxidase (HRP) polymer (DAKOCytomation) was added
for 30 minutes at room temperature. For SIX2 signal
amplification, Tyramide Signal Amplification (TSA) plus
Fluorescein isothiocyanate (FITC) fluorophore was diluted
in TSA amplification diluent and placed on sections for 10
minutes at room temperature (1:200 dilution; Perkin Elmer,
Waltham, MA). Unconjugated horseradish peroxidase was
quenched using 6% hydrogen peroxide in PBS for 15
minutes at room temperature. DAKO Envision antirabbit
HRP polymer (DAKOCytomation) was added for 30
minutes at room temperature. For CITED1 signal amplifica-
tion, TSA plus Cy3 flurophore (Perkin Elmer) was diluted in
TSA amplification diluent and placed on tissues for 10
minutes at room temperature. Nuclear counterstain was
performed using DAPI (1:50,000 dilution in PBS; Invitro-
gen, Eugene, OR) for 2 minutes at room temperature.
For MFKs, sections were similarly deparaffinized,
rehydrated, subjected to heat-induced epitope retrieval, and
quenched using hydrogen peroxide. Mouse fetal kidney
specimens were blocked using mouse-on-mouse block
(Vector Laboratories, Burlingame, CA) with 0.5% hydrogen
peroxide for 1 hour at room temperature. Sections were then
incubated in rabbit anti-CITED1 (1:100; Lab Vision Corp)
and mouse anti-SIX2 (1:100; Abnova) with mouse-on-
mouse block, 10% goat serum, and 0.5% hydrogen peroxide
in PBS overnight at 4°C. Antimouse HRP (1:750 dilution;
KPL, Gaithersburg, MD) was added for 40 minutes at room
temperature. For SIX2 signal amplification, TSA plus FITC
fluorophore was diluted in TSA amplification diluent and
placed on sections for 9 minutes at room temperature (1:200
dilution; Perkin Elmer). For visualization of CITED1,
antirabbit DyLight 549 secondary antibody was added
(1:600 dilution; Jackson Immunoresearch, West Grove,
PA) for 2 hours at room temperature.
1.4. Western blots
To quantify differences in protein expression across
various disease characteristics of WT, tissue lysates were
prepared by homogenizing snap-frozen WT specimens in
lysis buffer containing protease and phosphatase inhibitors
(150 mM NaCl, 1% Triton X, 5 mM EDTA, 50 mM
Hepes, 2.1 mM lepeptin, 0.15 mM aprotinin, 1 mM
Na2VO3, 50 mM NaF). Resulting protein tissue lysates
were quantified using a SpectraMax M5 spectrophotom-
eter (Molecular Devices, Sunnyvale, CA). Two hundred
micrograms of protein lysate for CITED1 and 100 μg of
lysate for SIX2 were heat-denatured and run on 10% Bis-
Tris NuPAGE electrophoresis gels in 1× MOPS NuPAGE
SDS running buffer at 200 V for 45 minutes at RT
(Invitrogen). Proteins were then transferred to PVDF
membranes in 1× NuPAGE transfer buffer (Invitrogen) at
30 V for 1 hour at 4°C. Immunoblots were performed
using affinity-purified rabbit anti-CITED1 (1:1000 dilu-
tion; Lab Vision Corp), rabbit anti-SIX2 (1:1000 dilution;
US Biological Corp), and mouse anti–β-actin (1:5000
dilution; Sigma Chemical Co, St. Louis, MO). Antibody-
antigen complexes were visualized with HRP-conjugated
secondary antibodies (goat antirabbit FC fragment specific
antibody 1:10000 dilution; Jackson Immunoresearch, and
goat antimouse secondary 1:1000 dilution; KPL). Speci-
ficity of SIX2 bands was confirmed using a second SIX2
antibody (1:5000 dilution, mouse monoclonal; Abnova).
Immunoblots were developed using Pierce ECL Western
blotting substrates (Thermo Scientific, Rockford, IL) and
visualized on x-ray radiograph. Bands were identified and
quantified using Photoshop software (Adobe, San Jose,
CA). Results were normalized to β-actin. MCF7, a breast
cancer cell line known to express CITED1, was used for
a CITED1-positive control. COS cell lysate, a trans-
formed monkey kidney cell line, was used for a negative
control. SIX2-positive controls were e18.5 MFKs and
VUWT, a WT also determined to have high SIX2
expression by immunohistochemistry and quantitative
real-time polymerase chain reaction (qRT-PCR). SIX2
negative controls were COS cell lysate and a congenital
mesoblastic nephroma.
1.5. Quantitative qRT-PCR
To evaluate differences in gene transcription of SIX2
and CITED1 across disease characteristics of WT, total
RNA was isolated and purified from snap-frozen WT
tissues using RNAzol (Tel-Test Inc, Friendswood, TX) and
RNeasy mini kits (Qiagen, Germantown, MD). Isolated
RNA was quantified using a SpectraMax M5 UV
spectrophotometer (Molecular Devices). Reverse transcrip-
tion of 3-μg RNA was performed using Superscript II
reverse transcriptase (Invitrogen) and oligo(dT) primers
(Applied Biosystems, Foster City, CA) to synthesize
complementary DNA suitable for analysis by quantitative
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qRT-PCR (Bio-Rad iCycler; Bio-Rad, Hercules, CA) using
iQ SYBR Green Super Mix (Bio-Rad). Primers used are
included below:
CITED1 forward: 5′-AGGATGCCAACCAAGAGATG-3′
CITED1 reverse: 5′-TGGTTCCATTTGAGGCTACC-3′
SIX2 forward: 5′-GCCGAGGCCAAGGAAAGGGAG-3′
SIX2 reverse: 5′-GAGTGGTCTGGCGTCCCCGA-3′
β-actin forward: 5′-GATGAGATTGGCATGGCTTT-3′
β-actin reverse: 5′-CACCTTCACCGTTCCAGTTT-3′
Changes in messenger RNA (mRNA) expression were
determined by comparison of sample cycle threshold values
against a standard curve generated using pooled sample or
plasmid complementary DNA. Results were normalized to
β-actin level and compared statistically.
1.6. Statistical analysis
One aim of this study was to determine whether quantities
of SIX2 or CITED1 expression correlated with patient or
disease variables including age, sex, stage of disease,
favorable or unfavorable histology, and treatment failure
(disease relapse or death). We also questioned whether
tumors with immunohistochemical detection of SIX2 in a
pattern reminiscent of the embryonic kidney correlated with
the above variables. Results from the above analyses were
compared among subsets of patients using the 2-sample
Wilcoxon's test (or the Kruskal-Wallis test for more than 2
groups). Nonparametric comparisons were performed be-
cause the distribution of study variables appeared to be long
tailed. To determine correlation between qPCR and Western
blot expression levels of CITED1 or SIX2, a nonparametric
measure of correlation was used (Spearman correlation
coefficient). Calculations were performed using the SAS
statistical software package (SAS, Cary, NC). Statistical
significance was set at P b .05.
2. Results
2.1. Immunohistochemistry
In 36 of 38 WT specimens suitable for examination, SIX2
was detected by immunohistochemistry (94.7%) (Fig. 1). In
24 specimens (63.2%), staining was restricted to the
blastemal compartment only. Nine specimens (23.7%)
showed concomitant blastemal and epithelial SIX2 immu-
nopositivity, and 3 specimens (7.9%) showed only epithelial
positivity. Regardless of blastemal or epithelial detection,
SIX2 was localized exclusively to the nucleus.
Expression of SIX2 was detected across all patient and
disease characteristics evaluated, including age, sex, stage,
histology, and treatment failure. Of the 38 specimens
analyzed by immunohistochemistry, 10 (26.3%) exhibited
a SIX2 immunostaining pattern reminiscent of that
observed in the embryonic kidney (Fig. 1A and B;
Fig. 1 Serial sections from a favorable histology WT show blastemal immunopositivity for SIX2 (A) and CITED1 (B). Epithelia and stroma
are immunonegative, similar to the embryonic kidney staining pattern (original magnification ×20). Serial sections from unfavorable histology
WT with similar overlap in blastemal expression of SIX2 (C) and CITED1 (D). Areas surrounding epithelial differentiation are weakly
CITED1 positive, but SIX2 negative, demonstrating divergent staining patterns unique to a proportion of tumors examined (original
magnification ×40). Normal kidney controls show immunonegativity for SIX2 (E) and CITED1 (F) (original magnification ×20).
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blastema positive, epithelia negative, stroma negative).
However, this staining pattern did not specifically associate
with age (P = .11), sex (P = 1.00), stage of disease (P =
.87), favorable or unfavorable histology (P = .27), or
treatment failure or success (P = .15). For this analysis, we
considered the WT blastema analogous to the cap
mesenchyme of the embryonic kidney.
CITED1 immunostaining was detected in 33 (86.8%) of
38 WT specimens examined. Twelve tumors (31.6%)
exhibited solely blastemal CITED1 immunostaining, where-
as 16 (42.1%) showed both blastemal and epithelial CITED1
positivity. Unlike SIX2, no tumors were detected with
exclusively epithelial CITED1 immunostaining. When serial
tumor sections were examined, immunodetection of SIX2
and CITED1 appeared to overlap in similar tumor histologic
compartments and regions, but some tumors showed unique
expression of one or the other protein between both
individual cells and larger tumor compartments (Fig. 1).
Neither CITED1 nor SIX2 was detected by immunohisto-
chemistry in normal kidney controls (Fig. 1E and F).
Immunohistochemical detection of SIX2 and CITED1 in
the e18.5 MFK was limited to the cap mesenchyme
surrounding the ureteric bud tips (Fig. 2A and B). A
population of SIX2+/CITED1− cells within the ventral cap
mesenchyme and in adjacent pretubular aggregates was
suggested by immunohistochemistry (Fig. 2A and B). To
further investigate the relationship between subcellular
localization and compartmental expression of SIX2 and
CITED1 within the MM and WT, we colocalized these
proteins using double immunofluorescence.
2.2. Immunofluorescence colabeling studies
Because SIX2 and CITED1 show both overlapping and
differential expression domains in the MM and WT, we tested
in which contexts these 2 proteins colocalized and whether any
associations with disease characteristics were evident accord-
ing to their differential expression or colocalization. Immuno-
fluorescent colabeling of the e18.5 MFK shows expression of
SIX2 and CITED1 in the dorsal cap mesenchyme surrounding
the ureteric bud tip epithelia (Fig. 2). In this embryonic context,
the subcellular localization of SIX2 is exclusively nuclear,
whereas CITED1 is detected predominantly in the cytoplasm
(Fig. 2C). Merged images of their respective expression
domains label an identical cell population within the cap
mesenchyme that expresses both SIX2 and CITED1; however,
a distinct population at the border of the ventral cap
mesenchyme and in pretubular aggregates appears to express
only SIX2 but not CITED1 (Fig. 2C). This experiment was
repeated using 16-week human fetal kidney specimens
showing similar findings (Fig. 3).
Colabeling of both unfavorable and favorable histology
WT shows SIX2 and CITED1 expression to be predom-
inantly nuclear and within the blastemal compartment of
tumors, although CITED1, and not SIX2, is concurrently
detected in the cytosol (Fig. 4). This nuclear enrichment of
CITED1 in malignant blastema is in marked contrast to its
predominantly cytosolic localization in the embryonic
kidney [10]. Among blastemal compartments, identical
cells were shown to express both SIX2 and CITED1;
however, rare blastemal cells, and even larger tumor
Fig. 2 Serial sections from e18.5 MFK show a population of cells in the ventral cap mesenchyme and in pretubular aggregates (arrowheads)
that are SIX2 positive (A), but CITED1 negative (B) (original magnification ×20). Double immunofluorescence for SIX2 and CITED1 on the
same section (C) identifies this SIX2-positive, CITED1-negative population in the ventral cap mesenchyme (arrowheads) (original
magnification ×20).
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regions, were observed to express either one or the other
protein (Fig. 4).
SIX2 expression in the developing kidney may be
observed in pretubular aggregates (Fig. 2), which represent
the earliest epithelial structure of the nephron but is not
observed in more mature nephronic epithelia. In WT, certain
primitive epithelial structures indeed expressed nuclear
SIX2; however, unlike the embryonic kidney, CITED1 was
also detected in primitive malignant epithelia and was
predominantly cytosolic in these more differentiated struc-
tures (Fig. 4).
2.3. Quantification of SIX2 and CITED1 expression
By Western blot, SIX2 and CITED1 were detected
broadly across all WT investigated and showed variable
quantity of expression among samples (Fig. 5). SIX2 was
visualized as a single band at 37 kd, and CITED1, as multiple
bands from 25 to 32 kd, consistent with previously described
variability in its molecular weight because of posttransla-
tional modifications [10,12]. Both SIX2 and CITED1 were
detected across all demographic and disease characteristics
of WT, regardless of patient age, sex, tumor stage, favorable
Fig. 3 Serial sections from a 24-week human fetal kidney show SIX2 (A) and CITED1 (B) immunopositivity corresponding to the cap
mesenchyme (original magnification ×20). Double immunofluorescence on a 16-week human fetal kidney demonstrates SIX2 (C) and
CITED1 (D) positivity in the cap mesenchyme (E, merged image) (original magnification ×20).
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or unfavorable histology, or treatment failure or success
(Fig. 5A, B, and C; Table). Likewise, similar levels of
SIX2 and CITED1 transcription were detected by qRT-
PCR across all WT regardless of patient or pathogenic
characteristics (Table).
Given the temporal and spatial overlap between SIX2
and CITED1 both in kidney development and in WT, we
used Western blot densitometry and qRT-PCR to
quantify the correlation between respective expression
levels across WT. Using a nonparametric measure of
correlation (Spearman correlation coefficient), the corre-
lation between SIX2 and CITED1 protein expression
normalized to β-actin was 0.42; the P value testing the
null hypothesis that the variables were independent was
.0081. Using qRT-PCR, the correlation between SIX2
and CITED1 mRNA expression was 0.28; the P value
testing the null hypothesis that the values were
independent was 0.08.
Fig. 4 Double immunofluorescence colocalizes SIX2 (A and E) and CITED1 (B and F) within the blastema of favorable histology WT.
Individual cells within the tumor blastema are heterogeneous with respect to SIX2 and CITED1 intensity (D and H). An area of aggregated
blastema is negative for SIX2 and CITED1 (G, asterisk; Bl indicates blastema, and St, stroma). Colocalization of SIX2 (I and M) and CITED1
(J and N) in unfavorable histology WT (L and P merged images). Areas of epithelial differentiation (K, asterisk) may be either positive for
SIX2 or CITED1 (L) or negative (O, Ep) depending on the tumor or region within a given tumor (A-D, original magnification ×20; E-P,
original magnification ×40).
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3. Discussion
This study is the first to characterize SIX2 expression
across a broad spectrum of WT. Our findings showed that the
expression of SIX2 and CITED1, transcriptional regulators
that specify self-renewing nephron progenitor cells in kidney
development, was highly consistent across WT regardless of
stage of disease, tumor histology, or treatment outcome.
Paralleling the MM of kidney development [13], SIX2 and
CITED1 were predominantly active in the blastemal
compartment of WT and in overlapping cell populations,
yet also showed independent expression domains within WT
compartments and in subcellular localization. Although
expression of these genes in WT did not associate with any
specific disease or demographic characteristic, the broad
detection of SIX2 and CITED1, genes that are normally
inactive in differentiated nephrons of the embryonic and
adult kidney, suggests that persistence or reactivation of
embryonal transcriptional programs is fundamental to
Wilms' tumorigenesis and, furthermore, implicates the
condensing MM as the WT cell population of origin.
The principal aim of this study was to clarify the
pathogenic significance of SIX2 across all stages and
histologies of WT. We were surprised to uncover the nearly
ubiquitous expression of this transcriptional regulator,
critical to nephronic progenitor self-renewal, across all
varieties of WT. Evidence is emerging to suggest that
embryonal transcriptional programs and other genes
expressed in the MM indeed remain active or are reactivated
in WT, including WT1 [14], PAX2 [15], SIX1, EYA1,
SALL2, HOXA11 [1], IGF2 [16], and CITED1 [10] genes.
The critical nature of genes expressed in the MM is further
underscored by the recent development of the first
endogenous genetic mouse model of WT by WT1 ablation
Fig. 5 Boxplot representation of SIX2 and CITED1 demonstrates ubiquitous expression across samples grouped by tumor stage (A),
histology (B), and treatment outcome (C; failure = relapse or death). (D) Western blots for SIX2 and CITED1 in favorable histology (FH) and
unfavorable histology (UH) WT specimens confirm ubiquitous expression, yet variability among samples. The CITED1 band at 27 kd was
used for densitometry and ran at same molecular weight as MCF7 positive control. Lower panels depict positive and negative controls (MCF7
indicates MCF7 cell lysate; COS, COS cell lysate; MFK, e18.5 MFK; CMN, congenital mesoblastic nephroma; VUWT, Wilms' tumor).
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and IGF2 overexpression [17]. Dysregulated activity of
SIX2 may well represent a prosurvival pathway for
malignant WT cells analogous to the condensing MM.
Other molecular factors important in renal progenitor cell
survival and function have been implicated in WT
pathogenesis, including the signal transducer STAT1
[18,19] and the chemokine receptor CXCR2 [20].
Although our data provide no mechanistic insight into the
role of SIX2 in WT, Aiden et al [21] recently characterized
the chromatin profile of WT specimens and identified a large
active chromatin domain that overlaps the SIX2 locus,
suggesting dysregulated epigenetic control of SIX2 in WT.
In addition, other developmentally relevant genes including
GDNF, SOX11, EYA1, and OSR1 were similarly identified
[21]. SIX2 promoter hypomethylation has also been detected
in a series of primary WT [22]. Taken together, these results
suggest that epigenetic mechanisms may function as critical
regulators of SIX2 expression in WT and raise the question
of whether WT cells exploit developmental pathways of self-
renewal for tumor initiation and growth. Indeed, previous
work from our laboratory supports the role of CITED1 in
tumor cell self-renewal as a regulator of cell proliferation and
tumorigenesis [10,11]. Ongoing efforts in our laboratory are
focused on determining the functional significance of SIX2
independent of and in combination with CITED1 in WT.
Perhaps disrupting these transcriptional programs could
attenuate cancer cell self-renewal and provide an avenue for
novel WT therapies.
Although similar expression of SIX2 and CITED1 was
detected across the aforementioned WT features, rare
instances were observed in which a given tumor region
expressed either one or the other protein alone. Heteroge-
neous expression of critical embryonal transcriptional pro-
grams within a given WT is not unprecedented. In fact,
activation of canonical Wnt signaling as estimated by nuclear
localization of β-catenin is often detected in as few as 5% of
cells within a given tumor [23,24]. Like SIX2 and CITED1
in the current study, nuclear localization of β-catenin has not
been associated with any specific pathogenic feature of WT
and may also be important in WT cancer cell survival or
tumorigenesis. Although differential expression of SIX2 and
CITED1 did not associate with any specific pathogenic
feature in the WTs provided for this study, perhaps these
expression patterns link a given WT to a specific progenitor
cell population or temporal stage in kidney development. For
example, a tumor with high SIX2 and low CITED1
expression could originate from the population of SIX2+/
CITED1− cells detected in the ventral cap mesenchyme and
in pretubular aggregates, as shown previously [4,13].
Alternatively, this tumor could originate from early nephro-
genesis when SIX2 expression in the cap mesenchyme has
commenced, but CITED1 expression has not [5]. In this way,
unique expression patterns may link a given WT to a specific
stage of kidney development and thereby expose other
candidate targets to promote terminal differentiation of WT.
The current study results differ slightly from our
previously published observations that showed CITED1
expression associated with stage IV disease in WT [10]. This
phenomenon is likely true in favorable histologyWT but was
not observed in the current investigation, possibly because of
the high proportion of unfavorable disease characteristics
examined herein. Furthermore, the tumors examined in the
current study were predominantly triphasic, whereas our
previous cohort contained a high proportion of blastemal
predominant tumors, which may express increased levels of
CITED1 given its propensity for strong blastemal detection
Table Median SIX2 and CITED1 expression by Western blot and qRT-PCR stratified according to patient demographics, WT stage,
histology, and treatment outcome
Characteristic n Median SIX2 normalized to β-actin Median CITED1 normalized to β-actin
Protein P mRNA P Protein P mRNA P
Age
0-23 mo 11 0.84 1.10 0.48 .00178
24+ mo 28 1.35 .34 1.01 .54 1.21 .03 .00352 .08
Sex
Male 19 1.21 1.19 0.91 .00311
Female 20 1.24 .62 0.72 .05 0.93 .76 .00317 .46
Stage
I 10 1.08 0.94 0.91 .00454
II 9 0.84 1.18 1.21 .00169
III 10 0.57 0.73 1.43 .00254
IV 10 1.66 .48 1.28 .38 0.63 .86 .00344 .43
Histology
Favorable 19 1.44 0.90 0.90 .00346
Unfavorable (anaplasia) 20 1.12 .51 1.10 .58 1.10 .50 .00253 .88
Outcome
Failure (relapse or death) 16 1.27 1.09 1.21 .00344
Nonfailure 23 1.21 .86 1.02 .49 0.86 .49 .00274 .61
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by immunohistochemistry. Additional limitations of this
study include the potential for sampling error, as small
regions from otherwise large tumors were analyzed. In
addition, this study was limited by the variability inherent in
obtaining specimens from a tissue bank (Children's
Oncology Group), whose source material may be subject
to inconsistent quality control with respect to specimen
acquisition, tissue fixation, and processing.
Our results support recent evidence that a complex
network of developmentally regulated transcriptional pro-
grams contributes to Wilms' tumorigenesis. Known genetic
mutations occur in less than 50% of WTs and have been
principally applicable as prognostic determinants [25]. In
light of the limited applicability of known genetic mutations
to the development of specific and novel cell-based
therapies, perhaps transcriptional activators that promote
cellular self-renewal will provide fertile ground for broadly
applicable therapeutic discoveries in WT.
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Discussion
Discussant, Dr Paul Losty (Liverpool, United Kingdom):
This is very interesting work. Have you looked for
colocalizations of stem cell markers?
Response, Dr Murphy: At this point, we can draw an analogy
between the expression of these 2 genes in Wilms' tumor
and the fact that the expression of these 2 genes in
development determines the stem cell phenotype. We've
characterized in separate studies the functional role of
CITED1 in Wilms' tumor, which seems to promote tumor
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cell self-renewal and tumorigenesis in vitro and in vivo.
We're currently working out the conditions to explore
those roles with SIX2. For now, we can draw an analogy
to development. We have not proven that those are stem
cells in the tumor themselves.
Discussant, Dr Mary Brandt (Houston, TX): You showed us
the tumor and you showed us the fetal kidney. How much
is this expressed in the adult or developed kidney?
Response, Dr Murphy: That's an excellent question. These 2
genes are off by the time nephrogenesis concludes, so
they are not expressed in the developed kidney whatso-
ever. They turn off at the very terminal stages of
nephrogenesis. There's actually a little bit of temporal
distinction between the 2 as well, SIX2 comes on earlier
in development and is present until the conclusion of
nephrogenesis, whereas CITED1 is expressed in a more
linear manner, so these are often noted in the adult kidney.
Discussant, Dr Brandt: If you took a kidney with Wilms'
tumor and stained it and did all these studies in the normal
kidney as well, there would be none in the normal and
how much in the tumor?
Response, Dr Murphy: That's correct, and the interesting
thing would be to look at the intermediate between the 2
which would be nephrogenic rests and in the limited
number of specimens that we have with nephrogenic
rests, they do stain positive for CITED1 and SIX2
suggesting that persistence of these stem cells in the
precursor lesion to Wilms' tumor also expresses these 2
key genes.
1249SIX2 and CITED1 in Wilms' tumor
